Skip to main content
. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y

Fig. 7. The molecular basis of YAP1 inhibitor in combination with immunotherapy in SCLC.

Fig. 7

High YAP1 expression induces PD-L1 expression, thus leading to the inhibition of T cells infiltration and function. The combinational treatment of YAP1 inhibitor and ICI significantly promotes apoptosis of tumor cells and activation of T cells. The addition of YAP1 inhibitor further enhances anti-tumor immunity. ICI immune checkpoint inhibitor, PD-1 program death-1, PD-L1 program death-ligand 1, SCLC small cell lung cancer, Treg regulatory T cells, YAP1 yes-associated protein 1.